[{"NetIncomeLoss_1_Q2_USD":-7393000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"PaymentsForRestructuring_2_Q2_USD":1818000.0,"AccountsPayableAndAccruedLiabilitiesCurrent_0_Q2_USD":5627000.0,"AssetsCurrent_0_Q2_USD":23949000.0,"RestructuringCharges_2_Q2_USD":1843000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":3477709.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":62000.0,"CommonStockSharesIssued_0_Q2_shares":31161941.0,"Assets_0_Q2_USD":31055000.0,"ShareBasedCompensation_2_Q2_USD":1639000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":4567000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":100000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":1440000.0,"CommonStockSharesAuthorized_0_Q2_shares":150000000.0,"OperatingIncomeLoss_2_Q2_USD":-13544000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":31109950.0,"OperatingIncomeLoss_1_Q2_USD":-7403000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":30623350.0,"GeneralAndAdministrativeExpense_2_Q2_USD":6476000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":5129000.0,"AssetsFairValueDisclosure_0_Q2_USD":487000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":7000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":7000.0,"CommonStockValue_0_Q2_USD":32000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":135000.0,"CostsAndExpenses_2_Q2_USD":21103000.0,"CostsAndExpenses_1_Q2_USD":7931000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-13487000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-7393000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":-2551000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":21342000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":3545000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":156588000.0,"Liabilities_0_Q2_USD":11814000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"DepreciationAndAmortization_2_Q2_USD":581000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":2802000.0,"RestructuringReserve_0_Q2_USD":25000.0,"InvestmentIncomeInterest_2_Q2_USD":50000.0,"InvestmentIncomeInterest_1_Q2_USD":3000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-16217000.0,"LiabilitiesCurrent_0_Q2_USD":8269000.0,"AccountsPayableCurrent_0_Q2_USD":632000.0,"NonoperatingIncomeExpense_2_Q2_USD":57000.0,"NonoperatingIncomeExpense_1_Q2_USD":10000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":22597000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_2_Q2_USD":35000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":2607000.0,"SeveranceCosts1_2_Q2_USD":1800000.0,"SeveranceCosts1_1_Q2_USD":100000.0,"DefinedContributionPlanEmployerDiscretionaryContributionAmount_2_Q2_USD":0.0,"DefinedContributionPlanEmployerDiscretionaryContributionAmount_1_Q2_USD":0.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":655000.0,"IncreaseDecreaseInOtherOperatingAssets_2_Q2_USD":-427000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":1284000.0,"NetIncomeLoss_2_Q2_USD":-13487000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":870000.0,"RestrictedCashNoncurrent_0_Q2_USD":1255000.0,"CommonStockSharesOutstanding_0_Q2_shares":31161941.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":-2000000.0,"ContractWithCustomerLiabilityCurrent_0_Q2_USD":312000.0,"PreferredStockValue_0_Q2_USD":null,"RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_2_Q2_pure":0.6,"LiabilitiesAndStockholdersEquity_0_Q2_USD":31055000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":1033000.0,"PreferredStockSharesAuthorized_0_Q2_shares":10000000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":1639000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":870000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":14627000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":1698000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-0.44,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.24,"ProfitLoss_2_Q2_USD":-13487000.0,"StockholdersEquity_0_Q2_USD":19241000.0,"RevenueFromContractWithCustomerIncludingAssessedTax_2_Q2_USD":7559000.0,"RevenueFromContractWithCustomerIncludingAssessedTax_1_Q2_USD":528000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-137379000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-16082000.0,"IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_Q2_USD":-1504000.0,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":-1003000.0,"Ticker":"COGT","CIK":"1622229","name":"UNUM THERAPEUTICS INC.","OfficialName":"Cogent Biosciences Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"369716293.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200811"}]